0
0
New Delhi – In a significant move to safeguard public health, the Delhi Government’s Drugs Control Department has launched a sweeping enforcement drive against the trade of illegal and counterfeit medicines. The intensified crackdown, executed under the “Zero Tolerance” policy of the Chief Minister Rekha Gupta-led administration, targeted major pharmaceutical hubs including the wholesale market at Bhagirath Palace and trading premises in Sadar Bazar.
The operation, carried out earlier this week, has uncovered alarming violations ranging from the sale of spurious anti-fungal creams to the operation of unlicensed medical device outlets. The drive highlights the administration’s commitment to rooting out the menace of falsified medical products that pose severe risks to patients across the capital and neighboring regions.
Raid Details: Uncovering a Shadow Trade
The enforcement drive was a coordinated effort involving the Drugs Control Department and the Delhi Police Cyber Cell. The most significant action took place at Bhagirath Palace, one of Asia’s largest wholesale drug markets. Departmental teams inspected 27 wholesale establishments, revealing that more than 10 firms were in contravention of the Drugs and Cosmetics Act, 1940.
During these inspections, officials collected 204 samples of various medical products, including syrups, tablets, surgical cotton, and other medical devices, to verify their compliance with safety standards. One establishment was booked specifically for selling medical devices and surgical items without a valid license, a clear violation of the Medical Devices Rules.
Simultaneously, a late-night joint raid was conducted in the Teliwara area of Sadar Bazar following specific intelligence inputs. This operation led to the seizure of a substantial quantity of counterfeit medicines, including fake branded topical formulations and anti-fungal creams. The premises were found to be operating without a drug license, and the operators failed to produce any purchase or sale records.
Official Stance: Zero Tolerance for Compromised Safety
Delhi Health Minister Dr. Pankaj Kumar Singh termed the operation a critical step in the government’s public health strategy.
“Ensuring the availability of safe and quality medicines is non-negotiable. We have zero tolerance for spurious, substandard, or illegally sold drugs and medical devices,” Dr. Singh stated. He emphasized that the administration is focused on strict regulatory oversight and that “intensified enforcement drives and coordinated action with law enforcement agencies will continue across Delhi to safeguard public health.”
Preliminary investigations from the Teliwara raid indicated a disturbing trend: the seized counterfeit medicines were not just for local consumption but were being supplied to adjacent states and even neighboring countries. In response, the Delhi Drugs Control Department has formally alerted its counterparts in neighboring states to ensure coordinated vigilance.
The Medical Perspective: A “Silent Killer”
The circulation of spurious drugs is not merely a legal violation but a profound medical hazard. Counterfeit medicines often contain incorrect ingredients, insufficient active pharmaceutical ingredients (APIs), or, in worst-case scenarios, toxic substitutes.
Dr. Sumol Ratna, a medical expert and Assistant Professor at NIIMS Medical College, warns of the grave consequences of consuming such products. “Counterfeit medicines can trigger severe adverse reactions, ranging from allergic responses to permanent organ damage,” Dr. Ratna explains. “In cases of chronic conditions like diabetes or hypertension, an ineffective fake drug leads to uncontrolled disease progression, which can result in heart attacks, strokes, or kidney failure. Furthermore, sub-therapeutic doses in fake antibiotics are a primary driver of antimicrobial resistance, a growing global health crisis.”
Experts note that spurious syrups, often contaminated with industrial solvents like diethylene glycol, have historically caused fatal kidney injuries in children, making the regulation of liquid formulations particularly critical.
Statistical Context and Public Health Implications
The scale of the challenge is significant. Recent data suggests that approximately 3.7% to 4% of drug samples tested in India fall under the “Not of Standard Quality” (NSQ) or spurious category. While this percentage might seem small, in a market as vast as India’s, it translates to millions of patients potentially receiving ineffective or harmful treatment.
The current drive’s collection of over 200 samples for testing is a proactive measure to ensure that the supply chain remains clean. The swift booking of offenders sends a strong deterrent message to the “fly-by-night” operators who often function without licenses or documentation.
Consumer Vigilance: A Critical Defense
While the government intensifies its crackdown, healthcare professionals advise consumers to remain vigilant.
“Patients should always purchase medicines from licensed pharmacies and insist on a proper bill,” advises Dr. V. Kanagasabhai, a senior medical administrator. “Check the packaging for any spelling errors, poor print quality, or broken seals. If a deal sounds too good to be true, especially online or from unauthorized sellers, it likely involves a counterfeit product.”
The Delhi Government has assured citizens that legal action against the defaulting firms will be swift and stringent, reinforcing the message that the health of the people remains the administration’s top priority.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
-
Delhi govt intensifies enforcement against illegal drug trade; action initiated against several firms at Bhagirath Palace. (2025, December 15). ANI News. Retrieved from https://www.aninews.in
-
